Navigation Links
Researchers discover novel method for detecting MIRCERA

Austrian researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced sensitivity for MIRCERA, but does not alter the performance characteristics of SDS-PAGE for detecting other EPOs. Details of this study, funded by a grant from the World Anti-Doping Agency (WADA), appear in the latest issue of Drug Testing and Analysis published by Wiley-Blackwell.

MIRCERA (methoxy polyethylene glycol-epoetin beta), a PEGylated EPO, is a synthetic protein that helps the body produce red blood cells and used to treat anemia caused by kidney disease. The drug is manufactured by Hoffmann-La Roche and only available outside the U.S. due to an infringement upon Amgen's patents on recombinant EPO products and processes. In the past, EPOs have been used off-label as doping agents by athletes to enhance endurance in such sports as cycling, distance running, and rowing. WADA has banned the use of EPOs, such as MIRCERA, in all competitive sports.

"The detection of doping with recombinant EPOs is one of the most challenging topics in anti-doping control," said Dr. Christian Reichel from the Seibersdorf Laboratories at the Austrian Institute of Technology (AIT) and lead author of the study. Dr. Reichel and colleagues obtained blood samples from four healthy volunteers as part of the study. Each participant received a single dose of each EPO drug (NeoRecormon (66 IU/kg), Dynepo (35 IU/kg), and MIRCERA (50 @g)). Samples were collected for at least 14 days (NeoRecormon, Dynepo) or up to 42 days post injection in the case of MIRCERA.

Researchers used a two-fold serial dilution of Dynepo (0.09 ng to 0.7 pg), NESP (0.07 ng to 0.5 pg), and MIRCERA (0.4 ng to 3.0 pg to compare the sensitivity of SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) for detecting MIRCERA by Western blotting. The intensity of the Dynepo and NESP bands gradually declined according to the decrease in their concentration, but a similar behavior was not observed for the MIRCERA bands. "We presumed from the experiments that the altered Western blotting performance of MIRCERA was due to its PEGylation (treatment with polyethylene glycol to obtain a long-acting effect of the protein)," noted Dr. Reichel.

PEGs of different average molecular masses (PEG 1500, 2000, 8000, 20000, 35000) were then separated on SDS-PAGE and visualized with a PEG-specific staining method. Due to a limited solubilizing power of SDS, PEGs regardless of molecular size were found to migrate as broad and smeared bands on SDS-PAGE. Given the results researchers hypothesized that the decreased sensitivity of MIRCERA on Western blots was due to an SDS-based solubility problem of MIRCERA's PEG-part.

To resolve the issue researches first used a detergent with higher solubilizing power for PEGs than SDS which did not improve the band shape of MIRCERA. Researchers then used SARCOSYL or (SAR)-PAGE with excellent results on Western blots by resolving MIRCERA in a sharp band and simultaneously keeping the resolution of rhEPOs and uhEPO on the performance level of SDS-PAGE. The authors found that "SARCOSYL was not binding to polyethylene glycol and was thus leaving PEGs in their native uncharged state." Redesigning SDS-PAGE by exchanging the SDS for SARCOSYL in the sample and running buffers solved the problem.

"In the past, there needed to be four methods performed to detect banned substances. Our method allows investigators to detect MIRCERA and other EPOs using just a single method," Dr. Reichel confirmed.


Contact: Dawn Peters

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
(Date:6/23/2016)... , June 23, 2016  Experian Health, ... and transforming the patient payment and care ... innovative new products and services that will ... revenue cycle offerings. These award-winning solutions will ... workflows, remain compliant in an ever-changing environment ...
Breaking Medicine Technology: